NCT02672475
- Conditions
- Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +10 more
- Locations
-
- Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States
Clinical trial condition
HER2/Neu Negative
Explore clinical trials studying HER2/Neu Negative. Study availability and eligibility vary by location and protocol.
55 public trials
3 recruiting studies
HER2/Neu Negative trial results
NCT04081389
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, +28 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
NCT03599453
- Conditions
- Anatomic Stage IV Breast Cancer AJCC, Breast Diseases, Breast Neoplasms, +9 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
NCT02401347
- Conditions
- Advanced Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more
- Locations
-
- Stanford Medicine at Stanford University Stanford, California, United States
NCT01846091
- Conditions
- Breast Diseases, Breast Neoplasms, Carcinoma, +21 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Completed
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
NCT02282345
- Conditions
- Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, +2 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
NCT02120469
- Conditions
- Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +9 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- City of Hope Rancho Cucamonga Rancho Cucamonga, California, United States
- South Pasadena Cancer Center South Pasadena, California, United States
Completed
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
NCT02536794
- Conditions
- Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +8 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- Northwestern University- Lake Forest Hospital Lake Forest, Illinois, United States
Completed
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
NCT03106077
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, +25 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
IACS-010759 in Advanced Cancers
NCT03291938
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, +46 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States